Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials.
Services
Services
Date issued
2014Journal title
Arthritis and Rheumatology
Type of content
Publicación de congreso
